春立医疗(688236) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 was RMB 805,857,022.19, a decrease of 33.32% compared to the previous year[2] - Operating profit for 2024 was RMB 130,711,152.28, down 57.28% year-on-year[6] - Net profit attributable to shareholders was RMB 124,984,999.16, a decline of 55.01% from the previous year[4] - Net profit after deducting non-recurring gains and losses was RMB 94,532,991.97, down 62.80% year-on-year[6] - Basic earnings per share decreased to RMB 0.33, a drop of 54.17% compared to the previous year[6] Assets and Equity - Total assets at the end of the reporting period were RMB 3,465,735,514.23, a decrease of 5.04% from the beginning of the period[3] - Equity attributable to shareholders was RMB 2,819,899,272.85, down 2.00% from the beginning of the period[3] Impact of Policies - The decline in revenue and profit was primarily due to the implementation of national centralized procurement policies, leading to price reductions for related products[5] - The company actively executed the national centralized procurement policy, resulting in a significant impact on performance[4] Investor Caution - The company warns investors that the financial data presented is preliminary and subject to audit, urging caution regarding investment risks[7]